ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/CDK4-selective
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/CDK4-selective
8
trial(s) found.
NCT07492641
Advanced
Phase 3
Recruiting
An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole Versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease (
KANDELA-302
)
CDK4/6 inhibitor
aromatase inhibitor
+ CDK4 selective inhibitor
Breast cancer
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - One Clinical Research
NCT07226349
Advanced
Phase 1
Recruiting
A Phase 1a/1b, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-75098 Alone and in Combination With Other Agents in Patients With Advanced Solid Tumors (
BG-75098-101
)
CDK2 inhibitor
+ CDK4 selective inhibitor
Solid tumour
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
WA
6009 - Nedlands - One Clinical Research
NCT06756932
Advanced
Phase 1
Recruiting
A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-21447 (a Bcl-2 Inhibitor) Combinations for Patients With HR+/HER2- Metastatic Breast Cancer (
BGB-21447-102
)
Bcl2 inhibitor
+ CDK4 selective inhibitor
Breast cancer
HER2-negative breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06120283
Advanced
Phase 1
Recruiting
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors (
BGB-43395-101
)
CDK4 selective inhibitor
Breast cancer
Cancer
HER2-negative breast cancer
HR-positive breast cancer
Non-small cell lung cancer
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2576 - Bowral - Southern Highlands Private Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - South Australia - GenesisCare St Andrews Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT05508906
Advanced
Phase 1
Recruiting
A Phase 1b Open-Label Multicenter Study of OP-1250 (Palazestrant) in Combination With the CDK4/6 Inhibitor Ribociclib, With the PI3K Inhibitor Alpelisib, With the mTOR Inhibitor Everolimus, or With CDK4 Inhibitor Atirmociclib in Adult Subjects With Advanced and/or Metastatic ER Positive, HER2 Negative Breast Cancer (
OP-1250-003
)
CDK4/6 inhibitor
PI3K alpha inhibitor
mTORC1 inhibitor
+ CDK4 selective inhibitor
Breast cancer
ER-positive breast cancer
HER2-negative breast cancer
NSW
2109 - North Ryde - Macquarie University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05216432
Advanced
Phase 1
Recruiting
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer (
RLY-2608-101
)
PI3K alpha inhibitor,allosteric,mutant-selective
+ CDK4 selective inhibitor
Breast cancer
HER2-negative breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
NCT04606446
Advanced
Phase 2
Recruiting
A PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS (
KAT6
)
KAT6A/B inhibitor
KAT6 inhibitor
+ CDK4 selective inhibitor
Breast cancer
Castrate-resistant prostate cancer
Non-small cell lung cancer
Prostate cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT03424005
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic Breast Cancer (
Morpheus-panBC
)
AKT inhibitor
Abemaciclib
Atezolizumab
Atirmociclib
Bevacizumab
CDK4/6 inhibitor
CDK4 inhibitor
CDK4 selective inhibitor
CDK6 inhibitor
Capecitabine
Carboplatin
ER degrader
Eribulin
Fulvestrant
Gemcitabine
Inavolisib
Ipatasertib
Ladiratuzumab Vedotin
Letrozole
Metformin
Nab-paclitaxel
PI3K alpha inhibitor
Palbociclib
Ribociclib
Sacituzumab Govitecan
Selicrelumab
Tocilizumab
Trastuzumab Deruxtecan
agnostic antibody,CD40-targeting
anti-CD40 agonistic antibody
anti-ERBB2 antibody-drug conjugate
anti-IL-6 monoclonal antibody
anti-LIV1 antibody-drug conjugate
anti-PD-L1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
anti-VEGF monoclonal antibody
antimetabolite
aromatase inhibitor
biguanide antihyperglycaemic agent
cancer therapy
cancer therapy,AKT-targeting
cancer therapy,CD40-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK4 selective-targeting
cancer therapy,CDK6-targeting
cancer therapy,ERBB2-targeting
cancer therapy,ESR1-targeting
cancer therapy,IL-6-targeting
cancer therapy,LIV1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,Trop2-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
endocrine therapy
endocrine therapy,oestrogen axis-targeting
fluoropyrimidine
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,CD40-targeting
immuno-oncology therapy,ERBB2-targeting
immuno-oncology therapy,IL-6-targeting
immuno-oncology therapy,LIV1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,Trop2-targeting
immuno-oncology therapy,VEGF-targeting
macrocyclic ketone analogue
oestrogen receptor-targeting therapy
pan-AKT inhibitor
platinum-based antineoplastic agent
selective estrogen receptor degrader
taxane
+ CDK4 selective inhibitor
Breast cancer
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
WA
6150 - Murdoch - Fiona Stanley Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (8)
Recruitment Country and State
NSW (7)
VIC (7)
WA (6)
QLD (4)
SA (2)
NZ (1)
Phase
Phase 1 (5)
Phase 1 / Phase 2 (1)
Phase 2 (1)
Phase 3 (1)
Trial Type
Advanced (8)
Cancer Therapy Class
CDK4
100%
CDK4 selective
100%
oestrogen axis
100%
ER
88%
CDK6
63%
PI3Kalpha
38%
CDK2
13%
Bcl2
13%
mTOR
13%
mTORC1
13%
KAT6
13%
KAT6A
13%
ER
13%
AKT
13%
CD40
13%
ERBB2
13%
IL-6
13%
LIV1
13%
PD-1/PD-L1
13%
PD-L1
13%
Trop2
13%
VEGF
13%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (6)
4575 - Birtinya - Sunshine Coast University Hospital (2)
6009 - Nedlands - One Clinical Research (2)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (2)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (2)
3021 - St Albans - Western Health - Sunshine Hospital (2)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
2109 - North Ryde - Macquarie University Hospital (2)
2500 - Wollongong - Wollongong Hospital (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
2139 - Concord - Concord Repatriation General Hospital (1)
2576 - Bowral - Southern Highlands Private Hospital (1)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
5000 - South Australia - GenesisCare St Andrews Hospital (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
3004 - Melbourne, Southbank - Alfred Health (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
Cancer Type
Cancer
Solid tumour
Breast cancer
Breast adenocarcinoma
HER2-negative breast cancer
HR-positive breast cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
ER-positive breast cancer
Castrate-resistant prostate cancer
Male genital cancers
Prostate adenocarcinoma
Prostate cancer
Urogenital cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy